Fabian Richter

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Acute Lymphoblastic Leukemia

Cancer Stem Cells

Inflammatory Response

Top Venues

Molecular cancer therapeutics

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Apostolia-Maria Tsimberidou, Kerstin Guenther, Borje S Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I Wistuba, David Fuhrmann, Nuhad K Ibrahim, Van Karlyle Morris, Bryan K Kee, Daniel M Halperin, Graciela Nogueras Gonzalez, Partow Kebriaei, Elizabeth J Shpall, David J Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer immunology research (2023)
Alexander Rau, Wolfgang S Lieb, Oliver Seifert, Jonas Honer, Dennis Birnstock, Fabian Richter, Nadine Aschmoneit, Monilola A Olayioye, Roland E Kontermann
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3. Molecular cancer therapeutics 19 (7) (2020)
Oliver Seifert, Alexander Rau, Nadine Beha, Fabian Richter, Roland E Kontermann
Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. mAbs 11 (5) (2019)
Fabian Richter, Oliver Seifert, Andreas Herrmann, Klaus Pfizenmaier, Roland E Kontermann
Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. mAbs 11 (4) (2019)
Fabian Richter, Kirstin A Zettlitz, Oliver Seifert, Andreas Herrmann, Peter Scheurich, Klaus Pfizenmaier, Roland E Kontermann
Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. mAbs 11 (1) (2018)